supports the appropriate use of biosimilars, because it will drive greater competition to release cost efficiencies, and in so doing support the treatment of an increasing number of patients and the uptake of new and innovative medicines.
This report from NHS England
summarises the output from two workshops on biosimilar medicines. Attendees included local stakeholders with decision-making responsibility for commissioning, prescribing, dispensing and monitoring biological medicines (including biosimilars), and patient representatives.
The workshop was designed to contribute to the development of a biosimilars implementation framework that will support people across the NHS to make appropriate use of biological medicines, including biosimilars.